Emergent BioSolutions

NYSE: EBS ↗$5.18 USD~$1.5B MCAP

#Biodefense #Infectious disease #Opioid overdose reversal

American multinational specialty biopharmaceutical company and global biodefense contractor; develops and manufactures medical countermeasures for biological threats and infectious diseases, including NARCAN nasal spray and anthrax vaccines. In August 2026 it eliminated the chief medical officer / head of R&D role in a sweeping restructuring.

Company Info

Sector:Biodefense / Specialty Biopharmaceuticals

Headquarters:Gaithersburg, Maryland, USA

Founded:1998

Website:www.emergentbiosolutions.com/

Upcoming Milestones & Key Dates

2026-08-05

Earnings

Q2 2026 results; multi-year transformation plan update

Clinical Development Pipeline

NARCAN (naloxone) nasal spray

Target: Opioid receptor antagonist

Opioid overdose reversal

Preclinical

Phase 1

Phase 2

Phase 3

Approved

BioThrax

Target: Anthrax vaccine

Anthrax prevention

Preclinical

Phase 1

Phase 2

Phase 3

Approved

VIGIV

Target: Vaccinia immune globulin

Vaccinia virus complications

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Narcan maker Emergent axes top R&D post in sweeping restructuring ↗

Emergent BioSolutions is eliminating the role of chief medical officer and head of R&D in a sweeping restructuring that leaves the Narcan maker without a dedicated C-suite R&D leader.

Leadership Team

Joseph C. Papa

President and Chief Executive Officer (since Feb 2024)

Careers & Job Openings

See all open roles

Apply Now →